Abstract
The aim of present study was to examine the bactericidal and antimicrobial activity of novel DA-5502 in gingivitis and periodontal diseases. The in vitro antimicrobial activity of DA-5502 was investigated against two strains Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans by biofilm and planktonic method. DA-5502 effectively inhibited both the biofilm formation and oral bacteria in planktonic state for both P. gingivalis and A. actinomycetemcomitans strains, which results in reduction of plaque and gum inflammation. The in vitro results provide scientific evidence that our novel DA-5502 liquid dentifrice formulation composed of cetylpyridinium chloride, dipotassium glycyrrhizinate, and panthenol as main active pharmaceutical ingredients, has effective adsorption capacity with excellent antimicrobial, antigingivitis, and antiplaque activity to treat periodontal diseases.
Similar content being viewed by others
References
Becker W, Becker BE, Berg LE (1984) Periodontal treatment without maintenance: a retrospective study in 44 patients. J Periodontol 55:505–509
Camargo FB Jr, Gaspar LR, Maia Campos PM (2011) Skin moisturizing effects of panthenol-based formulations. J Cosmet Sci 62:361–369
Darveau RP, Tanner A, Page RC (1997) The microbial challenge in periodontitis. Periodontol 2000 14:12–32
DePaola L, Minah GE, Overholser CD, Meiller TF, Charles CH, Harper DS, McAlary M (1996) Effect of an antiseptic mouthrinse on salivary microbiota. Am J Dent 9:93–95
Escribano M, Herrera D, Morante S, Teughels W, Quirynen M, Sanz M (2010) Efficacy of a low-concentration chlorhexidine mouth rinse in non-compliant periodontitis patients attending a supportive periodontal care programme: a randomized clinical trial. J Clin Periodontol 37:266–275
Fine DH, Furgang D, Barnett ML (2001) Comparative antimicrobial activities of antiseptic mouthrinses against isogenic planktonic and biofilm forms of Actinobacillus actinomycetemcomitans. J Clin Periodontol 28:697–700
Haffajee AD, Socransky SS (1994) Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 5:78–111
Herrera D, Santos S, Ferrus J, Barbieri G, Trombelli L, Sanz M (2005) Efficacy of a 0.15% benzydamine hydrochloride and 0.05% cetylpyridinium chloride mouth rinse on 4-day de novo plaque formation. J Clin Periodontol 32:595–603
Jorgensen MG, Slots J (2001) Antimicrobials in periodontal maintenance. J Dent Hyg 75:233–239
Kudiyirickal MG, Ivancakova R (2008) Antimicrobial agents used in endodontic treatment. Acta Medica 51:3–12
Lang NP, Catalanotto FA, Knopfli RU, Antczak AA (1988) Quality specific taste impairment following the application of chlorhexidine digluconate mouthrinses. J Clin Periodontol 15:43–48
Latimer J, Munday JL, Buzza KM, Forbes S, Sreenivasan PK, McBain AJ (2015) Antibacterial and anti-biofilm activity of mouth rinses containing cetylpyridinium chloride and sodium fluoride. BMC Microbiol 15:169
Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD (1984) Long-term effect of surgical/non-surgical treatment of periodontal disease. J Clin Periodontol 11:448–458
Loeshe WJ (1986) Role of Streptococcus mutans in human dental decay. Microbiol Rev 50:353–380
Mandel ID (1988) Chemotherapeutic agents for controlling plaque and gingivitis. J Clin Periodontol 15:488–498
Masatake T, Hidekazu K, Yasuhiko A, Toshiyuki T, Akira S, Toshio H (2000) The clinical evaluation of mouth rinse for periodontal disease. Jpn J Conserv Dent 43:703–711
Pitten FA, Kramer A (2001) Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic. Arzneimittelforschung 51:588–595
Quirynen M, Bollen CM, Vandekerckhove BN, Dekeyser C, Papaioannou W, Eyssen H (1995) Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short term clinical and microbiological observations. J Dent Res 74:1459–1467
Quirynen M, Soers C, Desnyder M, Dekeyser C, Pauwels M, van Steenberghe D (2005) A 0.05% cetyl pyridinium chloride/0.05% chlorhexidine mouth rinse during maintenance phase after initial periodontal therapy. J Clin Periodontol 32:390–400
Silva MF, dos Santos NB, Stewart B, DeVizio W, Proskin HM (2009) A clinical investigation of the efficacy of a commercial mouthrinse containing 0.05% cetylpyridinium chloride to control established dental plaque and gingivitis. J Clin Dent 20:55–61
Slots J, Rams TE (1991) New views on periodontal microbiota in special patient categories. J Clin Periodontol 18:411–420
Socransky SS, Haffajee AD (1992) The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 63:322–331
Sreenivasan PK, Haraszthy VI, Zambon JJ (2012) Antimicrobial efficacy of 005% cetylpyridinium chloride mouthrinses. Lett Appl Microbiol 56:14–20
Watanabe E, Tanomaru JMG, Nascimento AP, Matoba-Júnior F, Tanomaru-Filho M, Ito IY (2008) Determination of the maximum inhibitory dilution of cetylpyridinium chloride-based mouthwashes against Staphylococcus aureus: an in vitro study. J Appl Oral Sci 16:275–279
Williams MI (2011) The antibacterial and antiplaque effectiveness of mouthwashes containing cetylpyridinium chloride with and without alcohol in improving gingival health. J Clin Dent 22:179–182
Wu CD, Savitt ED (2002) Evaluation of the safety and efficacy of over-the-counter oral hygiene products for the reduction and control of plaque and gingivitis. Periodontol 28:91–105
Yoon WJ, Kim SS, Oh TH, Lee NH, Hyun CG (2009) Abies koreana essential oil inhibits drug-resistant skin pathogen growth and LPS-induced inflammatory effects of murine macrophage. Lipids 44:471–476
Acknowledgements
This article does not contain any studies with human and animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Kang MK, HG Park, and Jun JH are the employees of Dong-A ST Research Institute; all remaining authors have no conflict of interest.
Rights and permissions
About this article
Cite this article
Ruttala, H.B., Kang, M.K., Park, H.G. et al. Evaluation of antimicrobial effect of DA-5502 in gingivitis and periodontal diseases. J. Pharm. Investig. 48, 443–450 (2018). https://doi.org/10.1007/s40005-017-0328-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-017-0328-6